Evidence map›Paper›PMID 28494981›Full record

ReviewJournal of the American College of Cardiology2017

Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment.

Paul Muntner, Paul K Whelton

Abstract readReview
In one paragraph

Review in Journal of the American College of Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. The NaFrontiers in physiology · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Managing Hypertension in the elderly: What's new?American journal of preventive cardiology · 2020
    Review
  19. Strategies for prevention of cardiovascular disease in adults with hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Paul MuntnerDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: pmuntner@uab.edu.
Paul K WheltonDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana.

Funding

Incorporation of a Hypertension Working Group into the Jackson Heart StudyR01HL117323 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEWIS, CORA E, OGEDEGBE, OLUGBENGA G. · 2013 to 2024
$7.2M
NHLBI NIH HHS R01 HL117323
6 · The paper itself

Abstract

Using cardiovascular disease (CVD) risk instead of or in addition to blood pressure (BP) to guide antihypertensive treatment is an active area of research. The purpose of this review is to provide an overview of studies that could inform this treatment paradigm. We review data from randomized trials on relative and absolute CVD risk reduction that can occur when antihypertensive treatment is guided by CVD risk. We also review population-level data on using CVD risk in conjunction with BP to guide antihypertensive treatment, the broad distribution in CVD risk for people with similar BP levels, and the use of CVD risk for guiding antihypertensive treatment among subgroups including older adults, young adults, and those with diabetes mellitus or chronic kidney disease. In addition, we review potential challenges in implementing antihypertensive treatment recommendations that incorporate CVD risk. In closing, we provide recommendations for using CVD risk in combination with BP to guide antihypertensive treatment.

Indexed as

Blood PressureAntihypertensive AgentsCardiovascular DiseasesCost-Benefit AnalysisHumansRisk AssessmentAntihypertensive Agentshypertensionrisk predictiontreatment

Identifiers

PMID28494981
PMCPMC5873607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.